ClinicalTrials.gg
CompletedNCT00432315Updated Sep 14, 2010

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Docetaxel + CDDP and docetaxel + CDDP in Carcinoma, Squamous Cell, sponsored by Sanofi. Completed at 1 site in Austria. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-09-14.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies testing docetaxel in Carcinoma, Squamous Cell — 3 open to participants now, 3 under way, none of them phase 3. Docetaxel · Carcinoma, Squamous Cell.

Enrollment
7th of 20
80 · median 33
Started
2001
the only one that year
Phase 2
13 of 20
3 open now
Registered
4th of 20
by date
Lead sponsor
2 of 20
Sanofi

Among the 20 studies testing docetaxel in Carcinoma, Squamous Cell, this one is the 7th largest by enrollment, is the only one that started in 2001, is one of 13 in phase 2, and was the 4th registered.

Carcinoma, Squamous Cell

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

3 of the 20 studies testing docetaxel in Carcinoma, Squamous Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing docetaxel in Carcinoma, Squamous Cell, or all of them as a file.
02

Study summary

Primary objective:

  • To assess the response rate to induction therapy with docetaxel/CDDP.

Secondary objectives:

To assess

  • Resectability after induction therapy
  • Time to progression
  • Overall survival
  • Safety profile
  • Quality of Life
03

Conditions studied

  • Carcinoma, Squamous Cell
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histology and staging of the disease

    • or cytologically confirmed NSCLC; histology may include: large cell, squamous cell or adenocarcinoma but no SCLC
    • Resectable or unresectable NSCLC stage II (T1-2 N1, T3 N0) or stage IIIa (T1-2 N2 or T3 N1-2) or stage IIIb (T1-3 N3 or T4 N0-3)
    • (bidimensionally or unidimensionally according to WHO criteria)
  2. General conditions

    • Status > 70, if age > 70 years → PS > 70
    • Adequate hematological function ( > 10 g/dl, > 2.0 x 109/L, > 100 x 109/L)
    • Adequate renal and hepatic functions: total \< 1 x upper normal limit (UNL), serum creatinine \< 1 x UNL, in case of limit value the should be > 60 ml/min, ASAT and ALAT \< 2.5 x UNL, alkaline phosphatase \< 5 x UNL.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis

    • Evidence of or other distant equivalent to stage IV disease
    • History of prior , except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix or other curatively treated cancer with no evidence of disease for at least five years
    • Other serious concomitant illness or medical condition:

      • Congestive heart failure or angina pectoris, except if medically controlled, history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or arrhythmia
      • History of significant neurologic or psychiatric disorders, including dementia or seizure
      • Active infection requiring i.v. Antibiotics
      • Active ulcer, unstable diabetes mellitus or other to corticotherapy
    • Hepatic function abnormality: ASAT and/or ALAT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL
    • Current peripheral neuropathy WHO grade > 2
  2. Prior or concurrent therapy

    • Prior chemotherapy or immunotherapy for NSCLC, including or adjuvant treatment
    • Prior surgery or radiotherapy for NSCLC
    • Concurrent treatment with other experimental drugs, unapproved medical procedures or other anticancer therapy
  3. General conditions

    • Pregnant or lactating patients
    • Patients (M/F) with not implementing adequate measurements

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    1

    Resectable NSCLC

    Drug: Docetaxel + CDDP

  • Experimental
    2

    Unresectable NSCSC

    Drug: docetaxel + CDDP

Interventions

  • DrugDocetaxel + CDDP

    Drug pages: Docetaxel · Cisplatin

    * 3 cycles chemotherapy : docetaxel + CDDP * Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered) * 3 cycles adjuvant chemotherapy docetaxel

  • Drugdocetaxel + CDDP

    Drug pages: Docetaxel · Cisplatin

    * 3 cycles chemotherapy: docetaxel + CDDP * Radiochemotherapy * 3 cycles adjuvant chemotherapy docetaxel

06

What researchers measure

Primary outcomes

  1. To assess the response rate to induction therapy with docetaxel in combination with CDDP

    Time frame: every 3 months until tumour progression and thereafter every 6 months until death

Secondary outcomes

  1. Resectability after induction therapy

    Time frame: every 3 months until tumour progression and thereafter every 6 months until death

  2. Time to progression

    Time frame: every 3 months until tumour progression and thereafter every 6 months until death

  3. Overall survival

    Time frame: every 3 months until tumour progression and thereafter every 6 months until death

  4. Safety profile

    Time frame: throughout the study

  5. Quality of life

    Time frame: every 3 months until tumour progression and thereafter every 6 months until death

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2001, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2007
First posted
Feb 7, 2007
Start
May 2001
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
Sep 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00432315
Lead sponsor
Sanofi
First posted
Feb 7, 2007
Start date
May 2001
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Sep 14, 2010

Study contacts

Alexandra Edlmayer, Dr.
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cisplatin

Start the discussion